Multiply Labs Series B Backs Robots, but Pharma Still Has to Validate the Factory

Multiply Labs raised a $75 million Series B to move its robotic drug manufacturing platform from clinical deployments toward commercial production. NantWorks founder Patrick Soon-Shiong led the round, which pushes the San Francisco company’s total capital raised above $100 million.

The Multiply Labs Series B is more than another bet on laboratory automation. It tests whether robots can increase output without forcing drugmakers to abandon instruments, facilities, and manufacturing processes they have already validated.

That distinction places Multiply Labs between conventional manual production and competitors building centralized, highly integrated manufacturing networks. Its proposition is that pharmaceutical companies can install modular robotic clusters while retaining direct control of production, data, and supply chains.

The financing gives Multiply Labs resources to expand manufacturing capacity, accelerate product development, and hire across engineering, regulatory, and commercial functions. It does not settle the harder question. Drugmakers and regulators still need evidence that the platform can reproduce complex biological processes reliably at commercial scale.

The Multiply Labs Series B Funds a Commercial-Scale Push

The financing moves Multiply Labs from proving individual robotic workflows toward supporting regulated production at a much larger scale.

Multiply Labs announced the round on October 6, 2026. NantWorks led the investment, with participation from new and returning financial and strategic backers.

New investors named by the company include AstraZeneca, Lingotto, Teradyne, and Strange Ventures. Returning investors include Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund.

The mix matters because this is not a software product that can be tested through a limited cloud deployment. A pharmaceutical manufacturing system must work inside controlled facilities and alongside equipment governed by detailed operating procedures.

The company plans to use the capital to expand production of its robotic clusters. It also wants to move from clinical-stage installations toward systems capable of supporting commercial manufacturing.

That transition changes the standard by which the technology will be judged. A useful clinical deployment can process a limited number of batches under close supervision. Commercial production requires consistent operation across longer periods, larger volumes, and multiple sites.

Multiply Labs describes its equipment as clusters of robotic arms, instruments, software, and enclosed work areas. The robots execute timed, repetitive manufacturing tasks that trained operators often perform manually.

Those tasks can include moving materials between instruments, manipulating bags and tubing, taking samples, and coordinating process steps. The company connects its robots to equipment that pharmaceutical manufacturers already use.

This approach is intended to reduce the need for a completely new facility. It also aims to preserve validated instruments and established manufacturing practices wherever possible.

The company says customers own and operate each cluster themselves. Multiply Labs therefore differs from a contract manufacturer that receives a drugmaker’s process and produces therapies on the customer’s behalf.

Keeping the platform inside the pharmaceutical company’s operation offers strategic advantages. The manufacturer retains control of production schedules, process data, technical expertise, and supply-chain decisions.

It also retains responsibility for validating the system. That obligation includes showing that the equipment performs consistently and does not introduce unacceptable risks to product quality.

Multiply Labs says its technology now covers cell and gene therapies, antibodies, viral vectors, and mRNA products. These categories involve different materials and production steps, so breadth alone does not establish commercial readiness.

The significant change is organizational, not merely technical. Multiply Labs now has enough funding to build more systems, support additional installations, and create the teams required for regulated deployments.

Investors are financing the move from robotic demonstrations to manufacturing infrastructure. The success of the Multiply Labs funding round will ultimately depend on operating evidence, not the size of the syndicate.

Why Biologics Manufacturing Has Become the Constraint

Drug discovery can move quickly, but living cells and sensitive biological materials cannot be manufactured like ordinary software or standardized consumer goods.

Cell therapies illustrate the problem clearly. An autologous treatment begins with material collected from one patient and ends with a therapy returned to that same person.

Between those points, manufacturers may need to isolate cells, genetically modify them, expand them, test them, and prepare them for delivery. Each handoff introduces time, documentation, and contamination risks.

The physical product can also vary. Cells are living materials, and their behavior depends on the donor, process conditions, raw materials, and equipment used during production.

In conventional workflows, trained specialists transfer materials between separate instruments. They also document actions, monitor timing, and respond when a process moves outside an expected range.

This labor can become a capacity bottleneck. Adding more trained operators does not automatically create a proportional increase in output, especially when cleanroom space is limited.

Multiply Labs entered cell-therapy automation after earlier work on personalized capsules and small-batch drug production. An MIT company profile documented that shift in 2021.

At that time, the company was developing a platform with UCSF and Cytiva. Its aim was to run multiple bioreactors and automate tasks then performed by scientists.

The history matters because the current system did not appear as a response to the latest interest in physical AI. Multiply Labs has spent several years adapting robotics to pharmaceutical work.

However, longevity does not remove the manufacturing challenge. Robots must handle flexible bags, tubing, liquids, samples, and existing laboratory instruments without compromising sterility.

They must also operate within good manufacturing practice, or GMP. GMP refers to the controlled procedures, records, facilities, and quality systems used to make regulated medicines consistently.

A robot can repeat a movement accurately while the underlying biological process still varies. Manufacturers therefore need both mechanical repeatability and scientific controls that detect changes in the therapy itself.

The US Food and Drug Administration’s 2026 CMC guidance recognizes the unusual development challenges surrounding cell and gene therapies. CMC covers the chemistry, manufacturing, and controls information supporting a medicine’s quality.

The agency describes a flexible approach for certain development programs. That flexibility does not eliminate the requirement to produce safe, effective, and consistently manufactured biological products.

Automation can help by standardizing execution. Software can enforce sequences, capture timestamps, preserve electronic records, and reduce variation caused by manual handoffs.

Closed systems can also limit exposure to the surrounding environment. A closed system keeps material within controlled containers and connections during processing, reducing opportunities for contamination.

Those advantages explain the timing of the Multiply Labs Series B. Advanced therapies are progressing while their manufacturing processes remain difficult to scale.

The pressure falls on pharmaceutical companies with promising clinical programs. They need capacity before a therapy reaches commercial demand, yet they cannot casually change a process after generating clinical evidence.

A platform that integrates with existing instruments offers a possible middle route. It seeks to automate production without requiring every customer to redesign the entire process around proprietary equipment.

That compatibility is the central attraction. It is also the source of much of the engineering complexity.

Robotic Drug Manufacturing Without Rebuilding the Factory

Multiply Labs is betting that modular integration will beat a full factory replacement for drugmakers protecting validated processes.

The company’s robots do not attempt to replace every specialized instrument. Instead, they connect equipment and execute the physical steps between unit operations.

A unit operation is a defined manufacturing stage, such as cell separation, expansion, washing, formulation, or sampling. Each stage can involve a different machine and operating method.

This architecture resembles a robotic worker moving through an existing process. The cluster coordinates instruments, manages materials, and records how the workflow progresses.

Multiply Labs says its enclosed clusters can run continuously and adapt to changing conditions. Claims involving autonomous adaptation require careful interpretation in a regulated environment.

A pharmaceutical manufacturer cannot allow an algorithm to alter critical process behavior without defined controls. Any adaptive function must operate within an approved and validated range.

The useful form of autonomy is therefore bounded. A system might detect a misplaced object, recover from an interrupted movement, or schedule tasks across instruments.

It cannot independently rewrite a validated manufacturing process whenever conditions change. Quality personnel need to understand what the system did, why it acted, and whether the product remains acceptable.

Traceability becomes as important as movement. Each robotic action needs a record tied to the relevant batch, equipment, material, and operator authorization.

This is where software and robotics converge. The physical system performs the work, while the control layer preserves the evidence needed for investigation and release decisions.

Multiply Labs claims its clusters can reduce cost per dose by 74 percent and provide up to 100 times more throughput than manual manufacturing. Those figures come from the company and should not be treated as independent commercial benchmarks.

The improvement can also vary substantially by therapy. A workflow with many manual transfers may gain more from robotics than one already operating within integrated equipment.

Throughput depends on process duration, instrument capacity, quality testing, facility design, and staff availability. Faster material handling cannot eliminate a biological incubation period.

The system’s footprint may create another advantage. If multiple processes run within a compact enclosed cluster, a company can use cleanroom space more efficiently.

Yet dense equipment creates scheduling and maintenance challenges. One failure can affect several parallel workflows if they share robotic resources or common infrastructure.

Drugmakers will therefore examine redundancy, recovery procedures, spare parts, and service response. A manufacturing platform must remain supportable for the commercial life of a therapy.

Multiply Labs also needs to show that its approach transfers across sites. A system validated in one facility does not automatically perform identically elsewhere.

Environmental conditions, equipment configurations, operator practices, and local quality systems can differ. Software versions and hardware replacements must also be controlled over time.

These details make robotic drug manufacturing less visible than consumer robotics, but more consequential. A minor handling error can jeopardize a valuable batch or delay treatment for a specific patient.

The company’s strategy attempts to contain that risk through modularity and enclosure. Customers can automate selected operations while preserving the rest of their established process.

That can reduce initial disruption. It may also leave some manual interfaces in place, limiting the benefits of end-to-end automation.

The core mechanism behind the Multiply Labs funding story is therefore incremental integration. The company is not asking every pharmaceutical manufacturer to adopt one standardized factory model.

It is asking customers to place adaptable robots around the process they already trust. That proposition fits the industry’s caution, provided the resulting system remains verifiable.

The Main Rival Is a Different Manufacturing Model

Multiply Labs is competing against centralized automation strategies, not only against technicians performing repetitive work by hand.

Cellares offers the clearest comparison. The company operates an integrated development and manufacturing organization built around its Cell Shuttle automated platform.

Under that model, therapy developers can transfer processes into a network of specialized facilities. Cellares manages the manufacturing environment and offers capacity as a service.

Multiply Labs takes another path. Its customers own the robotic clusters and run them inside their own production operations.

The contrast concerns control, capital, and standardization. Centralized manufacturing can spread infrastructure and specialized staff across several customers.

An in-house cluster lets a drugmaker retain process knowledge and direct authority. It can also avoid dependence on an external manufacturer’s available production slots.

Neither model wins automatically. A smaller biotechnology company may lack the staff and facilities required to operate a robotic cluster.

A large pharmaceutical company may prefer internal capacity, especially for strategically important therapies. It may still use contract manufacturers to manage demand across regions or product stages.

Cellares has attracted substantial backing for its alternative. Its earlier factory financing supported facilities designed around an integrated production system.

The company said its New Jersey facility could accommodate 50 Cell Shuttles and produce 40,000 batches annually under specified assumptions. Those figures remain tied to its chosen processes and operating model.

Cellares has also pursued major manufacturing agreements with pharmaceutical companies. That commercial progress raises the standard for rivals seeking to prove adoption.

Multiply Labs can argue that its platform avoids a difficult process transfer into an external factory. Customers can maintain ownership while automating equipment already familiar to their teams.

The counterargument is that adapting one robotic platform to many customer environments can become expensive. Each installation may require engineering, validation, and integration work.

A standardized smart factory can concentrate those burdens. Once the facility and platform are qualified, additional programs may benefit from established infrastructure.

The market may support both routes. Advanced therapies differ too much in process, scale, ownership strategy, and geographic reach for one manufacturing model to cover every case.

Traditional equipment suppliers also remain relevant. Cytiva, Thermo Fisher Scientific, Lonza, and other manufacturers sell instruments and systems used throughout bioprocessing.

Some customers may prefer automation embedded directly in those platforms. Others may assemble semi-automated workflows from several suppliers without adopting a unifying robotic layer.

Industrial automation companies could become partners or future competitors. Teradyne’s participation in the Series B signals interest from a company with experience in robotics and automated testing.

Strategic investors can help Multiply Labs understand procurement and integration. Their involvement does not guarantee that affiliated companies will become large customers.

AstraZeneca’s participation is particularly notable because pharmaceutical manufacturers understand the cost of qualification. Still, an investment does not disclose the scale or status of any commercial deployment.

The main competitive question is whether modular ownership reduces enough friction to offset customization. Multiply Labs needs installations that become repeatable products rather than bespoke engineering projects.

If every new customer demands extensive redesign, growth will consume engineering resources. If clusters can support many workflows through controlled configuration, the platform can scale more efficiently.

That distinction separates an automation vendor from a project consultancy. The $75 million round gives Multiply Labs time to demonstrate which category it occupies.

What the Performance Claims Do Not Yet Establish

The strongest claims in the Multiply Labs Series B announcement remain company-reported and need validation under commercial operating conditions.

A 74 percent reduction in cost per dose would materially change manufacturing economics. Up to 100 times more throughput would also represent a major capacity improvement.

Those numbers lack enough public detail for broad comparison. The announcement does not provide a complete baseline, test protocol, product mix, facility configuration, or independent commercial dataset.

“Up to” results usually describe a favorable case. They do not tell customers what improvement to expect across different therapies and existing production systems.

Cost per dose can include labor, consumables, facility use, equipment depreciation, quality testing, maintenance, and failed batches. Excluding any category can substantially change the result.

Throughput also has several definitions. It might refer to doses per unit of floor space, processes per robot, batches per year, or output compared with a particular manual workflow.

Drugmakers will want results tied to their own process. They will also examine whether the system preserves critical quality attributes, which are measurable properties linked to product quality.

For cell therapies, those attributes can include identity, viability, purity, and potency. Potency describes the product’s biological ability to produce its intended effect.

A robot can complete a process faster while producing cells that differ from the clinical material. That outcome would create a comparability problem rather than a manufacturing improvement.

Comparability is the evidence showing that a product remains sufficiently consistent after a manufacturing change. It is crucial when companies automate processes already used for clinical development.

FDA manufacturing guidance describes the challenges associated with changes to cell and gene therapy production. The complexity of these products makes process transitions especially sensitive.

A company introducing Multiply Labs equipment may need analytical studies, engineering runs, validation batches, and regulatory discussions. The exact burden depends on the product’s development stage and the change involved.

Early adoption can be easier before a process becomes fixed. However, early-stage biotechnology companies have limited capital and may hesitate to install expensive infrastructure.

Late-stage and commercial programs have clearer demand. They also face higher switching costs because regulators have already reviewed the existing manufacturing approach.

This creates a narrow adoption window. Multiply Labs must engage customers early enough to shape production but late enough that programs have credible financing and clinical prospects.

The company also needs to prove reliability beyond successful runs. Customers will inspect failure rates, mean time between interventions, recovery procedures, and maintenance requirements.

Cybersecurity deserves attention because the platform combines connected software with physical production. Access controls, audit trails, updates, and remote support can all affect regulated operations.

A software patch cannot be handled like an ordinary application update. Manufacturers must assess whether it changes validated behavior and whether additional testing is required.

Supply-chain resilience presents another question. Customers need long-term access to replacement components, consumables, calibration services, and technical support.

Expansion into antibodies, viral vectors, and mRNA increases the addressable market. It also broadens the validation demands placed on the platform.

These products use different vessels, fluid paths, process durations, and environmental controls. A cluster that supports one category may require material changes for another.

Multiply Labs should therefore be judged on specific workflows rather than the breadth of its marketing language. Named deployments and reproducible operating data will matter more than category coverage.

Public information about installed systems remains limited. The company has discussed real-world deployments, but it has not released enough customer-level evidence to evaluate widespread commercial readiness.

That does not invalidate the platform. It means the Series B finances the proof stage that matters most.

Investors have accepted the technical and commercial risk. Pharmaceutical quality teams, regulators, and manufacturing leaders will apply a different standard before entrusting patient material to the robots.

Three Signals Will Show Whether the Bet Is Working

The next phase should be measured through validated deployments, repeatable economics, and regulatory acceptance rather than additional claims about physical AI.

The first signal is a named commercial-scale deployment. Multiply Labs needs a pharmaceutical customer to describe what the cluster manufactures and how it fits into a regulated process.

A useful disclosure would identify the therapy category, development stage, automated unit operations, and expected production capacity. It would also distinguish routine manufacturing from a pilot installation.

That evidence would strengthen the company’s argument that its equipment can move beyond supervised clinical-stage work. Continued reliance on unnamed projects would keep commercial adoption uncertain.

The second signal is performance data with clear baselines. Cost and throughput figures become more credible when customers or independent researchers explain what was measured.

Readers should look for batch counts, operating periods, intervention rates, failed-run data, and product-quality results. Comparisons should use equivalent processes and facility assumptions.

Evidence across several sites would be especially valuable. It would show whether Multiply Labs has created a repeatable platform or a collection of customized installations.

The third signal is regulatory use. A drugmaker could reference the robotic system in an investigational submission, a manufacturing amendment, or a biologics license application.

Regulators do not approve general-purpose manufacturing robots in isolation for every possible therapy. They evaluate the process, product, controls, and evidence presented by a sponsor.

That makes customer adoption more important than a broad regulatory label. Successful use within reviewed manufacturing processes would establish a practical path for later customers.

Investors should also watch the balance between product revenue and engineering services. A scalable hardware platform should gradually rely less on one-off integration work.

Hiring offers another clue. Expansion across regulatory and commercial teams suggests Multiply Labs understands that robotics alone cannot carry a pharmaceutical deployment.

Yet headcount and factory capacity do not prove demand. The strongest confirmation would combine repeat orders, customer expansion, and published manufacturing evidence.

The Multiply Labs Series B gives the company the capital to pursue those milestones. It also increases expectations for disclosure and commercial execution.

For pharmaceutical manufacturers, the immediate decision is not whether all biologics production will become robotic. Automation is already advancing through instruments, software, closed systems, and integrated factories.

The more useful question is which ownership model can pass validation while improving capacity. Multiply Labs offers an in-house, modular answer. Cellares and contract manufacturers offer more centralized alternatives.

Watch the first customers that move from pilot use into sustained production. Examine whether their quality teams report fewer interventions without creating new integration burdens.

Then compare the published economics with the headline claims. If commercial deployments approach the promised cost and throughput improvements, the round will have funded a meaningful manufacturing shift.

If validation remains slow and installations stay highly customized, the technology may remain valuable but narrower than its backers expect. The next evidence should come from operating factories, not another financing announcement.